Search Results

The Tisch MS Research Center of New York, the world’s largest MS research center, has announced publication of the results of its FDA-approved Phase II stem cell treatment study in a leading stem cell journal, Stem Cell Research & Therapy.

Indapta Therapeutics, Inc. announced that CEO Mark Frohlich, MD, will be giving a plenary talk today titled, “g-NK cells for the treatment of cancer and autoimmune disease” at the New York Academy of Sciences Frontiers in Cancer Immunotherapy Conference.

New research in the June 2024 issue of JNCCN—Journal of the National Comprehensive Cancer Network highlights a promising approach for alleviating distress, enhancing quality of life, improving physical function, and reducing fatigue in patients with blood cancers who undergo hematopoietic stem cell transplantation.

Houston-area clinical research organization Hope Biosciences Research Foundation shares topline results of a randomized, placebo-controlled Phase II study to evaluate Hope Biosciences’ adipose‑derived allogeneic mesenchymal stem cell therapy for patients with Post‑COVID‑19 syndrome.

While the companies did not reveal the financial details of the deal, Novo Nordisk will provide funding for two Evotec sites in Germany and Italy to support the development of next-generation cell therapies.

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell therapeutics for neurodegenerative diseases, will present new biomarker data suggesting that ALS patients may benefit from longer-term treatment with debamestrocel.

Seraxis, Inc., a regenerative medicine company developing pancreatic islet replacement therapies to transform the lives of patients with Type 1 and insulin-requiring Type 2 diabetes, has been notified that the company is the awardee of a $400,000 Commercialization Program grant from the Maryland Stem Cell Research Fund that aims to foster Maryland research to enhance and propel stem cell treatments.